Effect of simvastatin on endothelium-dependent vaso-relaxation and endogenous nitric oxide synthase inhibitor

Acta Pharmacologica Sinica

Volumn 25, Issue 7, 2004, Pages 893-901

  Jiang, Jun Lin ^a   Jiang, De Jian ^a   Tang, Yu Hai ^a   Li, Nian Sheng ^a   Deng, Han Wu ^a   Li, Yuan Jian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Endogenous nitric oxide synthase inhibitor; LDL lipoproteins; Simvastatin; Tumor necrosis factor; Vasodilation

Indexed keywords

ACETYLCHOLINE; DIMETHYLARGININASE; LOW DENSITY LIPOPROTEIN; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; OXIDIZED LOW DENSITY LIPOPROTEIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG POTENTIATION; ENDOTHELIUM; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INFLAMMATION; MONOCYTE; NONHUMAN; VASCULAR RING; VASODILATATION;

ANIMALS; ARGININE; CELL ADHESION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; LIPOPROTEINS, LDL; MALE; MONOCYTES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL CORD; VASODILATION;

EID: 3142736452     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-7.
2. Yu XJ, Li YJ, Xiong Y. Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits. Life Sci 1994; 54: 753-8.
3. Bode-Böger SM, Böger RH, Kienke S, Junker W, Frölich JC. Elevated L-arginine/dimethylarginie ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219: 598-603.
4. Chan JR, Boger RH, Bode-Boger SM, Tangphao O, Tsao PS, Blaschke TF, et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 2000; 20: 1040-6.
5. Boger RH, Bode-Boger SM, Tsao PS, Lin PS, Chan JR, Cooke JP. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 3: 2287-95.
6. van Haelst PL, Van Doormaal JJ, Asselbergs FW, Van Roon AM, Veeger NJ, Henneman MM, et al. Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolaemia. Clin Sci 2003; 104: 627-32.
7. Weis M, Pehlivanli S, Meiser BM, von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001; 38: 814-8.
8. Rezaie-Majd A, Maca T, Bucek RA, Valent P, Muller MR, Husslein P, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22: 1194-9.
9. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultra-centrifugally separated lipoproteins in human serum. J Clin Invest 1995; 34: 1345-53.
10. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-8.
11. Feng Q, Lu X, Jones DL, Shen J, Arnold JM. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 2001; 104: 700-4.
12. Li LX, Chen JX, Liao DF, Yu L. Probucol inhibits oxidized-low density lipoprotein-induced adhesion of monocytes to endothelial cells by reducing P-selectin synthesis in vitro. Endothelium 1998; 6: 1-8.
13. G-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 692: 467-71.
14. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-92.
15. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998; 62: 2425-30.
16. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-8.
17. Paiva H, Laakso J, Laine H, Laaksonen R, Knuuti J, Raitakari OT. Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. J Am Coll Cardiol 2002; 40: 1241-7.
18. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344: 160-2.
19. Frostegard J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 1991; 90: 119-26.
20. Frostegard J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA 1990; 87: 904-8.
21. Koba S, Pakala R, Watanabe T, Katagiri T, Benedict CR. Synergistic interaction between thromboxane A2 and mildly oxidized low density lipoproteins on vascular smooth muscle cell proliferation. Prostaglandins Leukot Essent Fatty Acids 2000; 63: 329-35.
22. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 1557-64.
23. Xiong Y, Li YJ, Yu XJ, Liu GZ, Li NS. Endogenous inhibitor of nitric oxide synthesis and lipid peroxidation in hyperlipidemic rabbits. Acta Pharmacol Sin 1996; 17: 149-52.
24. Jiang JL, Li NS, Li YJ, Deng HW. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol 2002; 135: 1175-82.
25. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-5.
26. Böger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87: 99-105.
27. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43: 542-8.
28. Kielstein JT, Bode-Boger SM, Frolich JC, Haller H, Boger RH. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int 2001; 78 (Suppl): S9-13.
29. Holm T, Aukrust P, Aagaard E, Ueland T, Haugstad TS, Kjekshus J, et al. Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertension. Transplantation 2002; 74: 1395-400.
30. Rezaie-Majd A, Prager GW, Bucek RA, Schernthaner GH, Maca T, Kress HG, et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2003; 23: 397-403.
31. Wang YX, Martin-McNulty B, Huw LY, da Cunha V, Post J, Hinchman J, et al. Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Atherosclerosis 2002; 162: 23-31.
32. Carneado J, Alvarez de Sotomayor M, Perez-Guerrero C, Jimenez L, Herrera MD, Pamies E, et al. Simvastatin improves endothelial function in spontaneously hypertensive rats through a superoxide dismutase mediated antioxidant effect. J Hypertens 2002; 20: 429-37.
33. Serrano CV Jr, Yoshida VM, Venturinelli ML, D'Amico E, Monteiro HP, Ramires JA, et al. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis 2001; 157: 505-12.
34. Paiva H, Laakso J, Lehtimaki T, Isomustajarvi M, Ruokonen I, Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 2003; 41: 219-22.
35. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003; 166: 279-84.
36. Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am Heart J 1993; 125: 958-73.
37. Mugge A, Elwell JH, Peterson TE, Harrison DG. Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol 1991; 260: C219-25.
38. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454-6.
39. Li H, Lewis A, Brodsky S, Rieger R, Iden C, Goligorsky MS. Homocysteine induces 3-hydroxy-3-methylglutaryl coenzyme a reductase in vascular endothelial cells: a mechanism for development of atherosclerosis? Circulation 2002; 105: 1037-43.
40. Koh KK, Son JW, Ahn JY, Jin DK, Kim HS, Choi YM, et al. Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002; 22: e19-23.
41. Ma FX, Liu LY, Xiong XM. Protective effects of lovastatin on vascular endothelium injured by low density lipoprotein. Acta Pharmacol Sin 2003; 24: 1027-32.